TT-OAD2

• UNSPSC Description:

  TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 has the potential for diabetes treatment[1][2].

• Target Antigen:

  GCGR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/tt-oad2.html

• Purity:

  99.77

• Solubility:

  DMSO : 110 mg/mL (ultrasonic)

• Smiles:

  O=C(O)[C@H](CC1=CC=C(C2=C(C)C(C)=NC=C2)C=C1)NC([C@H]3N([C@H](C4=CC=CC=C4)CC)CC5=C(C=C(OC[C@H](C6=CC=C(OCC7=CC=C(Cl)C(Cl)=C7)C=C6)O8)C8=C5)C3)=O.[H]Cl.[H]Cl

• Molecular Weight:

  929.75

• References & Citations:

  [1]Zhao P, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436.|[2]Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  No Development Reported

• CAS Number:

  2382719-60-8